Equities research analysts expect that Evolus Inc (NASDAQ:EOLS) will announce earnings of ($0.59) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Evolus’ earnings, with the highest EPS estimate coming in at ($0.51) and the lowest estimate coming in at ($0.67). Evolus posted earnings per share of $0.24 during the same quarter last year, which suggests a negative year-over-year growth rate of 345.8%. The business is expected to announce its next quarterly earnings results on Thursday, April 4th.
According to Zacks, analysts expect that Evolus will report full-year earnings of ($2.12) per share for the current year, with EPS estimates ranging from ($2.19) to ($2.05). For the next year, analysts forecast that the company will report earnings of ($3.51) per share, with EPS estimates ranging from ($4.56) to ($2.96). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Evolus.
Get Evolus alerts:
A number of analysts have recently issued reports on the company. Zacks Investment Research cut Evolus from a “hold” rating to a “sell” rating in a report on Thursday, November 8th. Stifel Nicolaus assumed coverage on Evolus in a report on Monday, January 28th. They set a “buy” rating and a $27.00 target price for the company. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. Evolus currently has an average rating of “Buy” and a consensus target price of $29.83.
EOLS traded down $2.20 during midday trading on Friday, hitting $26.71. The company’s stock had a trading volume of 2,471,590 shares, compared to its average volume of 1,544,451. Evolus has a 52-week low of $6.75 and a 52-week high of $39.50. The stock has a market capitalization of $788.52 million and a price-to-earnings ratio of -98.93.
In other news, Director Vikram Malik bought 7,800 shares of the firm’s stock in a transaction dated Monday, December 17th. The stock was acquired at an average price of $13.04 per share, for a total transaction of $101,712.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Kristine Romine bought 6,347 shares of the firm’s stock in a transaction dated Thursday, November 29th. The shares were purchased at an average price of $14.00 per share, with a total value of $88,858.00. The disclosure for this purchase can be found here. Insiders have bought a total of 17,147 shares of company stock valued at $228,880 in the last quarter.
Several large investors have recently modified their holdings of EOLS. Point72 Asset Management L.P. acquired a new position in Evolus during the 3rd quarter worth approximately $14,113,000. PointState Capital LP acquired a new position in Evolus during the 3rd quarter worth approximately $12,289,000. BlackRock Inc. lifted its position in Evolus by 51.6% during the 4th quarter. BlackRock Inc. now owns 933,601 shares of the company’s stock worth $11,110,000 after acquiring an additional 317,882 shares in the last quarter. Marshall Wace North America L.P. acquired a new position in Evolus during the 3rd quarter worth approximately $4,511,000. Finally, Vanguard Group Inc lifted its position in Evolus by 87.1% during the 3rd quarter. Vanguard Group Inc now owns 406,549 shares of the company’s stock worth $7,570,000 after acquiring an additional 189,277 shares in the last quarter. Institutional investors and hedge funds own 24.51% of the company’s stock.
Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
See Also: Understanding Analyst Ratings
Get a free copy of the Zacks research report on Evolus (EOLS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com